Richter’s 100% owned subsidiary dealing with microbial fermentation-based biomaterials, Richter BioLogics, has completed its investment in capacity expansion and Delivered its new state-of-the-art biotechnology plant in Boffenau, northern Germany. The company announced.
The total area of the multi-purpose factory has increased to about 10,000 square meters with the current expansion.
The new 300 and 1,500 litre production lines provide additional flexibility for simultaneous production of different products, enabling up to 120 batches per year to be produced. The facility also includes large laboratories for analytical testing, as well as warehouses and technical areas. By the end of 2024, the learners will be highly educated, The number of local employees will double according to the company's plans to exceed 400 people.
The new facility, together with its biotechnology facilities in Hungary, will provide Richter with integrated biotechnology R&D and production capabilities, helping patients access these medicines worldwide.
“It is a great honor to be associated with Gideon Richter Biotechnology,” said Eric Bocksch, President of Gideon Richter Biotechnology.
At the end of May, the acquisition was completed, under which Richter became 100 percent owner of Richter BioLogics, with the aim of strengthening the company in the field of biotechnology, a fast-growing but currently small business sector in Richter. The company is based in northern Germany, a leader in the production and development of microbiological contracts, with three locations, experienced management, more than 300 employees at the time and annual sales of around 60 million euros.
Cover image is an illustration. Cover image source: Getty Images
